-
1Academic Journal
Authors: A. V. Zharikova, K. P. Boriskina, E. V. Kondratyev, D. V. Sidorov, V. A. Nechaev, А. В. Жарикова, К. П. Борискина, Е. В. Кондратьев, Д. В. Сидоров, В. А. Нечаев
Contributors: Работа выполнена по инициативе авторов без привлечения финансирования.
Source: Medical Visualization; Принято в печать ; Медицинская визуализация; Принято в печать ; 2408-9516 ; 1607-0763
Subject Terms: радиомика, resectable and borderline resectable tumor, locally advanced tumor, assessment of response to neoadjuvant chemotherapy, post-chemotherapy computed tomography, radiomics, резектабельная и погранично-резектабельная опухоль, местнораспространенная опухоль, оценка ответа на неоадювантную химиотерапию, компьютерная томография после химиотерапии
File Description: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/1524/930; Saad A.M., Turk T., Al-Husseini M.J., Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018; 18 (1): 688. http://doi.org/10.1186/s12885-018-4610-4; Егоров В.И., Петров Р.В., Амосова Е.Л., Харазов А.Ф., Петров К.С., Журина Ю.А., Кондратьев Е.В., Зельтер П.М., Дзигасов С.О., Григорьевский М.В. Дистальная резекция поджелудочной железы с резекцией чревного ствола вместе с правой или левой печеночной артерией без артериальной реконструкции (расширенная DP-CAR). Хирургия. Журнал им. Н.И. Пирогова. 2021; 10: 13 28. https://doi.org/10.17116/hirurgia202110113; Tamm E.P., Bhosale P.R., Vikram R. et al. Imaging of pancreatic ductal adenocarcinoma: State of the art. Wld J. Radiol. 2013; 5 (3): 98–105. https://doi.org/10.4329/wjr.v5.i3.98; Khasawneh H., Ferreira Dalla Pria H.R., Miranda J. et al. CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy: Current Statusand Perspective on the Use of Radiomics. J. Clin. Med. 2023; 12 (21): 6821. https://doi.org/10.3390/jcm12216821; Soloff E.V., Al-Hawary M.M., Desser T.S. et al. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review. Am. J. Roentgenol. 2022; 218 (4): 570–581. https://doi.org/10.2214/AJR.21.26931; Zhang Y., Huang Z.X., Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. Wld J. Gastroenterol. 2021; 27 (22): 3037–3049. https://doi.org/10.3748/wjg.v27.i22.3037; Egorov V., Kim P., Dzigasov S. et al. Pancreatectomy with En Bloc Superior Mesenteric Vein and All Its Tributaries Resection without PV/SMV Reconstruction for “Low” Locally Advanced Pancreatic Head Cancer. Cancers (Basel). 2024; 16 (12): 2234. https://doi.org/10.3390/cancers16122234; Buchs N.C., Chilcott M., Poletti P.-A. et al. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. Wld J. Gastroenterol. 2010; 16 (7): 818–831. https://doi.org/10.3748/wjg.v16.i7.818; Al-Hawary M.M., Francis I.R., Chari S.T. et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014; 270 (1): 248–260. https://doi.org/10.1148/radiol.13131184; Жарикова А.В., Кондратьев Е.В., Тихонова В.С., Груздев И.С., Ростовцев М.В., Марков П.В., Стручков В.Ю., Кармазановский Г.Г. Влияние современных технологий компьютерной и магнитно-резонансной томографии на дооперационное стадирование рака поджелудочной железы. Медицинская визуализация. 2024; 28 (2): 118–133. https://doi.org/10.24835/1607-0763-1452; NCCN 2024, https://www.nccn.org; Katz M.H., Fleming J.B., Bhosale P. et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012; 118 (23): 5749–5756. https://doi.org/10.1002/cncr.27636; Ferrone C.R., Marchegiani G., Hong T.S. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. AnnSurg. 2015; 261: 12–17. https://doi.org/10.1097/SLA.0000000000000867; Wang Z.J., Arif-Tiwari H., Zaheer A. et al. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom. Radiol (NY). 2020; 45 (12): 4273–4289. https://doi.org/10.1007/s00261-020-02723-z; Zins M., Matos C., Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018; 287 (2): 374–390. https://doi.org/10.1148/radiol.2018171670; Zimmermann C., Distler M., Jentsch C. et al. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). Strahlenther Onkol. 2021; 197 (1): 19–26. https://doi.org/10.1007/s00066-020-01654-4; Perik T.H., van Genugten E.A.J., Aarntzen E.H.J.G. et al. Quantitative CT perfusion imaging in patients with pancreatic cancer: a systematic review. Abdom. Radiol. (NY). 2022; 47 (9): 3101–3117. https://doi.org/10.1007/s00261-021-03190-w; Кармазановский Г.Г., Кондратьев Е.В., Груздев И.С., Тихонова В.С., Шантаревич М.Ю., Замятина К.А., Сташкив В.И., Ревишвили А.Ш. Современная лучевая диагностика и интеллектуальные персонализированные технологии в гепатопанкреатологии. Вестник Российской академии медицинских наук. 2022; 77 (4): 245–253. https://doi.org/10.15690/vramn2053; Tikhonova V.S., Karmazanovsky G.G., Kondratyev E.V. et al. Radiomics model-based algorithm for preoperative prediction of pancreatic ductal adenocarcinoma grade. Eur. Radiol. 2023; 33 (2): 1152–1161. https://doi.org/10.1007/s00330-022-09046-1; Ciaravino V., Cardobi N., DE Robertis R. et al. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. Anticancer Res. 2018; 38 (8): 4889–4895. https://doi.org/10.21873/anticanres.12803; Chen X., Oshima K., Schott D. et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS One. 2017; 12 (6): e0178961. https://doi.org/10.1371/journal.pone.0178961; Kim B.R., Kim J.H., Ahn S.J. et al. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur. Radiol. 2019; 29 (1): 362–372. https://doi.org/10.1007/s00330-018-5574-0.; Замятина К.А., Жарикова А.В., Кондратьев Е.В., Усталов А.А., Староверов Н.Е., Нефедьев Н.А., Гожева А.Р., Шмелева С.А., Кармазановский Г.Г. Оценка диагностической ценности глубокого машинного обучения для автоматизированной сегментации паренхимы поджелудочной железы и ее гипо- и гиперваскулярных образований по КТ-изображениям с помощью U-net нейросети. Медицинская визуализация. 2024; 28 (3): 12–21. https://doi.org/10.24835/1607-0763-1483; https://medvis.vidar.ru/jour/article/view/1524
-
2Academic Journal
Authors: Alexandra V. Zharikova, Evgeny V. Kondratyev, Valeriya S. Tikhonova, Ivan S. Gruzdev, Mikhail V. Rostovtsev, Pavel V. Markov, Vladimir Yu. Struchkov, Grigory G. Karmazanovsky, А. В. Жарикова, Е. В. Кондратьев, В. С. Тихонова, И. С. Груздев, М. В. Ростовцев, П. В. Марков, В. Ю. Стручков, Г. Г. Кармазановский
Source: Medical Visualization; Том 28, № 2 (2024); 118-133 ; Медицинская визуализация; Том 28, № 2 (2024); 118-133 ; 2408-9516 ; 1607-0763
Subject Terms: МРТ, вовлечение сосудов, местнораспространенная опухоль, неоадъювантная химиотерапия, КТ
File Description: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/1452/873; ACS Journals, Cancer statistics 2020, http://doi.org/10.3322/caac.21590; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. 2021.; Park W., Chawla A., O’Reilly E.M. Pancreatic Cancer: A Review. JAMA. 2021; 326 (9): 851–862. https://doi.org/10.1001/jama.2021.13027; Buchs N.C., Chilcott M., Poletti P.-A. et al. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. Wld J. Gastroenterol. 2010; 16 (7): 818–831. https://doi.org/10.3748/wjg.v16.i7.818; Al-Hawary M.M., Francis I.R., Chari S.T. et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014; 270 (1): 248–260. https://doi.org/10.1148/radiol.13131184; Клинические рекомендации Министерства здравоохранения РФ “Рак поджелудочной железы, 2021 год” https://cr.minzdrav.gov.ru/schema/355_4; Gugenheim J., Crovetto A., Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022; 74 (1): 35–42. https://doi.org/10.1007/s13304-021-01186-1; Seufferlein T., Uhl W., Kornmann M. et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) – a randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol. 2023; 34 (1): 91–100. https://doi.org/10.1016/j.annonc.2022.09.161; Ghaneh P., Palmer D., Cicconi S. et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 2023; 8 (2): 157–168. https://doi.org/10.1016/S2468-1253(22)00348-X; NCCN Guidelines for Pancreatic Adenocarcinoma. V.1., 2023.; Lee E.S., Lee J.M. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. Wld J. Gastroenterol. 2014; 20 (24): 7864–7877. https://doi.org/10.3748/wjg.v20.i24.7864; Kim Y.K., Lee M.W., Lee W.J. et al. Diagnostic Accuracy and Sensitivity of Diffusion-Weighted and of Gadoxetic Acid-Enhanced 3-T MR Imaging Alone or in Combination in the Detection of Small Liver Metastasis (≤1.5 cm in Diameter). Invest. Radiol. 2012; 47 (3): 159–66. https://doi.org/10.1097/rli.0b013e31823a1495; Кармазановский Г.Г. Опухоли поджелудочной железы солидной структуры: стадирование и резектабельность, критерии оценки прогрессирования опухолевого процесса после хирургического лечения (лекция, часть 2). Медицинская визуализация. 2016; 5: 43–49.; Шима В., Кауэлблингер К. Аденокарцинома поджелудочной железы: выявление, определение стадии и дифференциальная диагностика. Медицинская визуализация. 2015; 5: 52–72.; Ветшева Н.Н. Дооперационная диагностика солидных опухолей поджелудочной железы: обзор литературы. Медицинская визуализация. 2016; 5: 50–58.; Kamisawa T., Takuma K., Anjiki H. et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am. J. Gastroenterol. 2010; 105 (8): 1870–1875. https://doi.org/10.1038/ajg.2010.87; Uzunoglu F.G., Welte M.-N., Gavazzi F. et al. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Eur. J. Surg. Oncol. 2019; 45 (5): 793–799. https://doi.org/10.1016/j.ejso.2018.12.012; Sohal D.P.S., Kennedy E.B., Cinar P. et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J. Clin. Oncol. 2020; 38 (27): 3217–3230. https://doi.org/10.1200/JCO.20.01364; Isaji S., Mizuno S., Windsor J.A. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018; 18 (1): 2–11. https://doi.org/10.1016/j.pan.2017.11.011; Покатаев И.А., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Кучин Д.М., Лядов В.К. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022; 12: 530–544. https://doi.org/10.18027/2224-5057-2022-12-3s2-530-544; Fujita T., Nakagohri T., Gotohda N. et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas. 2010; 39 (1): e48–54. https://doi.org/10.1097/MPA.0b013e3181bd5cfa; Kanda M., Fujii T., Nagai S. et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011; 40: 951–955. https://doi.org/10.1097/MPA.0b013e3182148342; Sergeant G., Melloul E., Lesurtel M. et al. Extended lymphadenectomy in patients with pancreatic cancer is debatable. Wld J. Surg. 2013; 37 (8): 1782–1788. https://doi.org/10.1007/s00268-013-2064-z; Zacharias T., Jaeck D., Oussoultzoglou E. et al. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J. Gastrointest. Surg. 2007; 11: 350–356. https://doi.org/10.1007/s11605-007-0113-3; Henne-Bruns D., Vogel I., Lüttges J. et al. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. Wld J. Surg. 2000; 24 (5): 595–601; discussion 601–602. https://doi.org/10.1007/s002689910089; Murakami Y., Uemura K., Sudo T. et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann. Surg. Oncol. 2011; 18 (3): 651–658. https://doi.org/10.1245/s10434-010-1325-4; Henne-Bruns D., Vogel I., Lüttges J. et al. Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology. 1998; 45 (21): 855–866. PMID: 9684147; Masui T., Kubota T., Aoki K. et al. Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report. Wld J. Surg. Oncol. 2013; 11 (1): 195. https://doi.org/10.1186/1477-7819-11-195; Kaťuchová J., Bober J., Kaťuch V., Radoňak J. Significance of lymph node micrometastasis in pancreatic cancer patients. Eur. Surg. Res. 2012; 48 (1): 10–15. https://doi.org/10.1159/000334171; Ishikawa O., Ohhigashi H., Sasaki Y. et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann. Surg. 1988; 208 (2): 215–220. https://doi.org/10.1097/00000658-198808000-00014; Nimura Y., Nagino M., Takao S. et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: Long-term results of a japanese multicenter randomized controlled trial. J. Hepatobiliary. Pancreat. Sci. 2012; 19: 230–241. https://doi.org/10.1007/s00534-011-0466-6; Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14: 101–112. https://doi.org/10.1007/s10120-011-0041-5; Базин И.С., Покатаев И.А., Попова А.С., Базина И.В., Чихарева Я.Е. Место химиотерапии в лечении локализованного рака поджелудочной железы. Злокачественные опухоли. 2016; 4 (спецвыпуск 1): 20–25. https://doi.org/10.18027/2224-5057-2016-4s1-20-25; Lambert A., Schwarz L., Ducreux M., Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel). 2021; 13 (18): 4724. https://doi.org/10.3390/cancers13184724; Springfeld C., Ferrone C.R., Katz M.H.G. et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 2023; 20 (5): 318–337. https://doi.org/10.1038/s41571-023-00746-1; Katz M.H., Fleming J.B., Bhosale P. et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012; 118 (23): 5749–5756. https://doi.org/10.1002/cncr.27636; Ferrone C.R., Marchegiani G., Hong T.S. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann. Surg. 2015; 261: 12–17. https://doi.org/10.1097/SLA.0000000000000867; Zins M., Matos C., Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018; 287 (2): 374–390. https://doi.org/10.1148/radiol.2018171670; Chen X., Oshima K., Schott D. et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS One. 2017; 12 (6): e0178961. https://doi.org/10.1371/journal.pone.0178961; Navez J., Bouchart C., Lorenzo D. et al. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Ann. Surg. Oncol. 2021; 28 (11): 6211–6222. https://doi.org/10.1245/s10434-020-09568-2.; Barreto S.G., Loveday B., Windsor J.A., Pandanaboyana S. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J. Surg. 2019; 89 (5): 481–487. https://doi.org/10.1111/ans.14764; Yang R., Lu M., Qian X. et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J. Cancer. Res. Clin. Oncol. 2014; 140 (12): 2077–2086. https://doi.org/10.1007/s00432-014-1728-x; Zimmermann C., Distler M., Jentsch C. et al. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). Strahlenther. Onkol. 2021; 197 (1): 19–26. https://doi.org/10.1007/s00066-020-01654-4; Nishiofuku H., Tanaka T., Marugami N. et al. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur. Radiol. 2016; 26 (6): 1835–1842. https://doi.org/10.1007/s00330-015-3999-2; Cozzi L., Comito T., Fogliata A. et al. Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS One. 2019; 14 (1): e0210758. https://doi.org/10.1371/journal.pone.0210758; Nasief H., Hall W., Zheng C. et al. Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9. Front. Oncol. 2020; 9: 1464. https://doi.org/10.3389/fonc.2019.01464; Ciaravino V., Cardobi N., De Robertis R. et al. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. Anticancer Res. 2018; 38 (8): 4889–4895. https://doi.org/10.21873/anticanres.12803; Chen F., Zhou Y., Qi X. et al. CT texture analysis for the presurgical prediction of superior mesenteric-portal vein invasion in pancreatic ductal adenocarcinoma: comparison with CT imaging features. Clin. Radiol. 2021; 76 (5): 358–366. https://doi.org/10.1016/j.crad.2021.01.003; Rigiroli F., Hoye J., Lerebours R. et al. CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Radiology. 2021; 301 (3): 610–622. https://doi.org/10.1148/radiol.2021210699; Bian Y., Jiang H., Ma C. et al. Performance of CT-based radiomics in diagnosis of superior mesenteric vein resection margin in patients with pancreatic head cancer. Abdom. Radiol. (NY). 2020; 45 (3): 759–773. https://doi.org/10.1007/s00261-019-02401-9; https://medvis.vidar.ru/jour/article/view/1452